Joseph McLaughlin, MD
Medical Oncology · Manchester, CTNPI 1013178466
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $172,749 of the $199,994 with a category attached, or 86.4%. E.r. Squibb & Sons, L.L.C. accounts for 96.1% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2021 at $80,607 and has fallen 100.0% since, to $24 in 2025. Among medical oncology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $858.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$192K
- Bristol Myers Squibb$5K
- Regeneron$1K
- Pfizer$157
- Johnson & Johnson$142
- Novartis$133
- plus $1K from 30 others
Across 21 payments — averaging $1236.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$19K
- Bristol Myers Squibb$7K
What the payments were for
- Consulting fees$20,52410%
- Speaking & faculty fees$172,74986%
- Travel & lodging$1,6261%
- Food & beverage$4,8732%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 124 | $192,205 |
| Bristol Myers Squibb | 5 | $5,081 |
| Regeneron | 1 | $1,215 |
| Pfizer | 16 | $157 |
| Johnson & Johnson(2 entities) | 10 | $142 |
| Novartis | 9 | $133 |
| Merck | 9 | $122 |
| Genentech USA, Inc. | 8 | $116 |
| Amgen | 6 | $107 |
| AstraZeneca(2 entities) | 4 | $78 |
| Incyte Corporation | 4 | $60 |
| Tesaro, Inc. | 2 | $53 |
| Bayer | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| GSK | 1 | $33 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $30 |
| Gilead | 2 | $30 |
| Exelixis Inc. | 2 | $29 |
| AbbVie | 2 | $29 |
| Astellas Pharma US Inc | 2 | $29 |
| Lilly USA, LLC | 2 | $29 |
| Puma Biotechnology, Inc. | 2 | $27 |
| Seagen Inc. | 2 | $26 |
| Eisai Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Dova Pharmaceuticals | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Fortovia Therapeutics, Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| Heron Therapeutics, Inc. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| EMD Serono, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$199,994 in reported general payments places this provider in the 90th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 91 | $1,209,636 |
| IbrancePalbociclib | 66 | $1,045,933 |
| TagrissoOsimertinib Mesylate | 34 | $579,335 |
| Lenalidomide | 33 | $455,969 |
| Abiraterone Acetate | 217 | $446,560 |
| NubeqaDarolutamide | 31 | $414,975 |
| TruqapCapivasertib | 18 | $403,030 |
| ImbruvicaIbrutinib | 24 | $339,642 |
| BosulifBosutinib | 16 | $297,933 |
| XtandiEnzalutamide | 22 | $288,777 |
| CalquenceAcalabrutinib Maleate | 15 | $225,448 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $194,015 |
| Neulasta OnproPegfilgrastim | 23 | $152,928 |
| Pazopanib Hcl | 11 | $121,807 |
| XareltoRivaroxaban | 99 | $106,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Bosulif, Eliquis | $157 | $1,428,942183 claims |
| Bristol Myers SquibbRevlimid | $5,081 | $1,209,63691 claims |
| AstraZenecaTagrisso, Truqap, Calquence | $78 | $1,207,81267 claims |
| BayerNubeqa | $45 | $414,97531 claims |
| Astellas Pharma US IncXtandi | $29 | $288,77722 claims |
| NovartisMekinist | $133 | $194,01512 claims |
| Johnson & JohnsonXarelto, Procrit | $142 | $141,694117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 medical oncology providers in Connecticut.
Other medical oncology in Manchester
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- William OhGreenwich$162K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
- Lajos PusztaiNew Haven$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.